Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2015-01-26Clinical Trial Update: Pilot Study to Evaluate MR-guided Laser Ablation of Focal Lesions in Patients With Medically Refractory Partial Epilepsy [Phase 1]
This clinical trial update reports the completion of a Phase 1 pilot study evaluating MR-guided laser ablation of focal lesions in patients …
-
FDA approval · 2015-01-24FDA Approved: LEVETIRACETAM — Supplemental Application (SOHM, Inc.)
FDA approved a supplemental application for Levetiracetam from SOHM, Inc. under an ANDA.
-
CLINICAL_TRIALS research · 2015-01-21Clinical Trial Update: Trobalt™ Products Risk Survey
GlaxoSmithKline reports a completed risk survey related to Trobalt (ezogabine) for epilepsy.
-
FDA approval · 2015-01-20FDA Approved: OXCARBAZEPINE — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
The FDA approved a supplemental application for oxcarbazepine from Glenmark Pharmaceuticals Inc., USA (ANDA 077802).
-
FDA approval · 2015-01-20FDA Approved: CARBAMAZEPINE — Supplemental Application (Torrent Pharmaceuticals Limited)
FDA approved a supplemental application for Carbamazepine from Torrent Pharmaceuticals Limited, indicating an approved action on an existing…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2015-01-20FDA Approved: EPITOL — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for EPITOL (carbamazepine) from Teva Pharmaceuticals USA, Inc.
-
FDA approval · 2015-01-20FDA Approved: OXCARBAZEPINE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for Oxcarbazepine submitted by Sun Pharmaceutical Industries, Inc.
-
FDA approval · 2015-01-20FDA Approved: OXCARBAZEPINE — Supplemental Application (Breckenridge Pharmaceutical, Inc.)
The FDA approved Breckenridge Pharmaceutical, Inc.'s supplemental application for oxcarbazepine under the ANDA.
-
FDA approval · 2015-01-16FDA Approved: VALPROIC ACID — Supplemental Application (QUAGEN PHARMACEUTICALS LLC)
FDA approves a supplemental application for Valproic acid from Quagen Pharmaceuticals LLC (ANDA 090517).
-
CLINICAL_TRIALS trial_result · 2015-01-13Clinical Trial Update: Effect of Repeated Administration of Eslicarbazepine Acetate on the Pharmacokinetics of Simvastatin in Healthy Subjects [Phase 1]
Phase 1 trial evaluating whether repeated administration of eslicarbazepine acetate affects the pharmacokinetics of simvastatin in healthy s…
-
CLINICAL_TRIALS trial_result · 2015-01-12Clinical Trial Update: Comparative Bioavailability Study of Two Different Sources of Eslicarbazepine Acetate [Phase 1]
This document reports a Phase 1 comparative bioavailability study of two sources of eslicarbazepine acetate conducted by Bial - Portela C S.…
-
CLINICAL_TRIALS trial_result · 2015-01-12Clinical Trial Update: An Open-label, Multiple-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093 [Phase 1]
An open-label Phase 1 pharmacokinetic study of BIA 2-093 in epilepsy has completed, and its results have been posted.
-
CLINICAL_TRIALS trial_result · 2015-01-08Clinical Trial Update: Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy Volunteers [Phase 1]
A Phase 1 trial assessing tolerability and pharmacokinetics of a single 900 mg oral dose of BIA 2-093 with oxcarbazepine in healthy voluntee…
-
CLINICAL_TRIALS trial_result · 2015-01-08Clinical Trial Update: Food Effect and Dosage Form Proportionality Study of Eslicarbazepine Acetate [Phase 1]
Phase 1 study evaluating the food effect and dosage form proportionality of eslicarbazepine acetate has been completed and results posted.
-
CLINICAL_TRIALS trial_result · 2015-01-08Clinical Trial Update: Pharmacokinetic Interaction Study Between Eslicarbazepine Acetate and Carbamazepine [Phase 1]
Phase 1 pharmacokinetic interaction study evaluating eslicarbazepine acetate with carbamazepine in epilepsy; results have been posted after …
-
CLINICAL_TRIALS withdrawal · 2015-01-08Clinical Trial Update: Effect of Music Therapy on Cognitive Recovery [NA]
A clinical trial evaluating music therapy for cognitive recovery in epilepsy has been withdrawn.
-
FDA approval · 2015-01-07FDA Approved: DEPAKOTE ER — Supplemental Application (AbbVie Inc.)
The FDA approved a supplemental application for Depakote ER (divalproex sodium) filed by AbbVie Inc., resulting in a regulatory update to th…
-
CLINICAL_TRIALS trial_result · 2015-01-07Clinical Trial Update: A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic Profile and CNS Effects of BIA 2-093 [Phase 1]
A Phase 1 double-blind, randomized, placebo-controlled, rising multiple-dose study assessed safety, tolerability, steady-state pharmacokinet…
-
CLINICAL_TRIALS trial_result · 2015-01-07Clinical Trial Update: A Single Centre, Phase I, Double-blind, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetic Profile and Effects on EEG of Single Rising Oral Doses of BIA 2-093 [Phase 1]
Phase I trial evaluating safety, tolerability, pharmacokinetics, and EEG effects of single rising oral doses of BIA 2-093 in epilepsy; study…
-
CLINICAL_TRIALS trial_result · 2015-01-01Clinical Trial Update: Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy Volunteers [Phase 1]
Phase 1 study evaluating the steady-state pharmacokinetics of the candidate BIA 2-093 and oxcarbazepine in healthy volunteers to inform dosi…
-
CLINICAL_TRIALS trial_result · 2015-01-01Clinical Trial Update: Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of BIA 2-093 [Phase 1]
Phase 1 trial evaluating single-dose pharmacokinetics and relative bioavailability of an oral suspension and two tablet formulations of BIA …
-
CLINICAL_TRIALS trial_result · 2014-12-31Clinical Trial Update: Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its Metabolites [Phase 1]
A Phase 1 pharmacokinetic study assessing single-dose and steady-state exposure of BIA 2-093 and its metabolites in the context of epilepsy.
-
CLINICAL_TRIALS trial_result · 2014-12-31Clinical Trial Update: The Effect of BIA 2-093 on the Steady-state Pharmacokinetics of Digoxin [Phase 1]
Phase 1 study assessing whether BIA 2-093 alters the steady-state pharmacokinetics of digoxin.
-
CLINICAL_TRIALS trial_result · 2014-12-31Clinical Trial Update: An Open-label, Single-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093 [Phase 1]
Open-label Phase 1 single-dose pharmacokinetics study of BIA 2-093 in epilepsy, completed with results posted in 2014.
-
FDA approval · 2014-12-30FDA Approved: LAMICTAL — Supplemental Application (GlaxoSmithKline LLC)
FDA approved a supplemental application for LAMICTAL (lamotrigine) from GlaxoSmithKline, updating the product labeling as a result of the su…